Protective effect of Liquiritigenin on H9C2 cardiomyocytes apoptosis induced by high glucose

doi:10.12092/j.issn.1009-2501.2019.02.005

Abstract

Abstract:

AIM: To evaluate the potential effect and mechanism of Liquiritigenin on apoptosis of H9C2 cardiomyocytes induced by high glucose. METHODS: H9C2 cardiomyocytes were cultured and were divided into the following groups: control group, high glucose group (HG group), high glucose with Liquiritigenin treated group (final concertration: 10, 30, 100 nmol/L). CCK-8 assay was used to detected cell viability. Malonaldehyde (MDA) levels and superoxide dismutase (SOD) activity were measured by certain kits. Reactive oxygen species (ROS) production and the percentage of apoptosis of the H9C2 cardiomyocytes were determined by flow cytometry. Western blot was used to evaluate the expression levels of Bcl-2 and Bax. RESULTS:CCK-8 assay demonstrated that Liquiritigenin (final concertration: 30, 100 nmol/L) significantly enhanced cell viability after high glucose treated (P<0.05, P<0.05). Meanwhile, Liquiritigenin (final concertration: 30, 100 nmol/L) decreased the generation of MDA (P<0.05，P<0.05) and ROS (P<0.05，P<0.05), but increased the activity of SOD (P<0.05，P<0.05). Moreover, Liquiritigenin (final concertration 100 nmol/L) reduced apoptosis rate by high glucose though increasing the ratio of Bcl-2/Bax ratio (P<0.01). CONCLUSION: Liquiritigenin protected H9C2 cardiacmyocytes from high glucose injury through reducing oxidative stress and apoptosis.

Key words: Liquiritigenin, high glucose, cardiomyocytes, oxidative stress, apoptosis

CLC Number:

ZHUO Fengqiao, HUANG Zhanhong, LIU Yujie. Protective effect of Liquiritigenin on H9C2 cardiomyocytes apoptosis induced by high glucose[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 147-151.

References

［1］赵航冯, 景辉, 吴秀萍. 糖尿病心肌病发病机制的研究进展［J］. 国际心血管杂志, 2016, 43(1): 16-18.
［2］Huynh K, Bernardo BC, McMullen JR, et al. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways［J］. Pharmacol Ther, 2014, 142(3): 375-415.
［3］Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease ［J］. Apoptosis, 14(4): 536-548.
［4］Liu J, Viswanadhapalli S, Garcia L, et al. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer［J］. Oncotarget, 2017, 8(30): 50002-50014
［5］Tao W, Dong Y, Su Q, et al. Liquiritigenin reverses depression-like behavior in unpredictable chronic mild stress-induced mice by regulating PI3K/Akt/mTOR mediated BDNF/TrkB pathway ［J］. Behav Brain Res, 2016, 308: 177-186.
［6］张岩，冯超，韩吉春. 甘草素减轻大鼠离体心肌缺血再灌注损伤作用研究［J］. 天然产物研究与开发, 2017, 29: 1492-1497.
［7］Xie XW. Liquiritigenin attenuates cardiac injury induced by high fructose-feeding through fibrosis and inflammation suppression ［J］. Biomed Pharmacother, 2017, 86: 694-704.
［8］Huang Z, Sheng Y, Chen M, et al. Liquiritigenin and liquiritin alleviated MCT-induced HSOS by activating Nrf2 antioxidative defense system ［J］. Toxicol Appl Pharmacol, 2018, 15, 355: 18-27.
［9］庸晋，刘畅，曹文君，等. 糖毒性对心肌细胞损伤的研究［J］. 国际心血管杂志，2015, 42 (3): 183-185.
［10］Selvaraju V, Joshi M, Suresh S, et al. Diabetes, oxidative stress, molecular mechanism, and cardiovascular disease-an overview［J］. Toxicol Mech Methods, 2012, 22(5): 330-335.
［11］Giacco F, Brownlee M. Oxidative stress and diabetic complications［J］. Circ Res, 2010, 107(9): 1058-1070.
［12］lliamson CL, Dabkowski ER, Baseler WA, et al. Enhanced apoptotic propensity in diabetic cardiac mitochondria：influence of subcellular spatial location［J］. Am J Physiol Heart Circ Physiol, 2010, 298(2): H633-H642.
［13］Cai L, Li W, Wang G, et al. Hyperglycemia-induced apoptosis in mouse myocardium Mitochondfial cytochrome C-mediated caspase-3 activation pathway［J］. Diabetes, 2002, 51: 1938-1948.
［14］Czabotarp E, Guillaume L, Andreas S, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy ［J］. Nat Rev Mol Cell Biol, 2014, 15(1): 49.
［15］Vassort G, Turan B. Protective role of antioxidants in diabetesinduced cardiac dysfunction［J］. Cardiovas Toxicol, 2010, 10(2): 73.

[1]	LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin. Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
[2]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[3]	LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin. The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
[4]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[5]	YANG Xiaojia, JIANG Meng, WU Min, ZHANG Yili, LV Lan, WU Yuanfen, WANG Xinyu, LIU Liquan. Improvement effect of crocin on cognitive impairment of Alzheimer's disease rats through DKK3 regulation of GSK-3 β/β-Catenin pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 489-497.
[6]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[7]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[8]	BAI Jia, YANG Hong, LI Lingling, ZHANG Yangyang, YANG Ying, LV Haihong. Study on the effect of vitamin D on diabetic neuropathy through mitochondrial/autophagy pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 214-219.
[9]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[10]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[11]	ZHU Haobin, YUE Hongmei, WU Xingdong, LIU Miaomiao, LI Yating, XU Jinhui. Research progress on the role of the Nrf2 signaling pathway in the complications associated with obstructive sleep apnea [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1283-1291.
[12]	YANG Zhian, ZHAO Yan, HE Yao, LIU Weiying, YU Qin. Pyroptosis mediated renal injury caused by chronic intermittent hypoxia and the intervention effect of edaravone in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 10-18.
[13]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[14]	HUA Haiyan, YAN Jie, QIN Yufen. Experimental study of schisandrin B attenuates acute myocardial ischemia injury in rats by inhibiting cardiomyocyte apoptosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 848-856.
[15]	WANG Jinhuo, GAO Xinyue, GUO Jianrong. Effect of COX-2 inhibitors on postoperative delirium in elderly patients undergoing orthopedic surgery and its possible mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 863-869.